Takeda Pharmaceutical Company Limited provided consolidated earnings guidance for year ending March 31, 2023. For the period, the company expected revenue of JPY 3,690,000 million, operating profit of JPY 520,000 million, profit attributable to owners of parent of JPY 292,000 million, Basic earnings per share of JPY 188.13 per basic share.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,089 JPY | -0.02% | +0.49% | +0.86% |
26/04 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
26/04 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.86% | 40.76B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- Takeda Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for Year Ending March 31, 2023